Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared Melbourne, Australia, and Basel, Switzerland – Oct 5, 2026 – CSL...

KING OF PRUSSIA, Pa., September 29, 2026 | CSL today announced a collaboration with Amazon Web Services (AWS) to apply artificial intelligence and cloud technologies to support the company’s...

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress

Dear Hemophilia B Community, We are writing to share an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived...

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic...

Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University...

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct....

Melbourne, Australia – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are:...